Starpharma: VivaGel(R) Condom Receives TGA Device Certification - Launch Preparations to Follow
Business Wire - Sun Jul 20, 10:05PM CDT
Starpharma (ASX:SPL) (OTCQX:SPHRY) today announced achievement of a major milestone with the receipt of Conformity Assessment Certification for the VivaGel(R) condom by the Australian Therapeutic Goods Administration (TGA). This TGA certification is similar to CE certification of devices (CE Mark) in Europe.
ANN: 38.11 (+0.58)
FDA Grants Special Protocol Assessment (SPA) Agreement for Starpharma Phase 3 Recurrent BV Trial
Business Wire - Mon Jul 14, 4:35AM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel(R) bacterial vaginosis (BV) product for the prevention of recurrent BV.